Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.47 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.45 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.45 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.45 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29464219 | 1.00 | PARP1 (0.48) | PARP1ALOX5GRIN2DGRIN3BGRIN1 | |
| SCHEMBL31334775 | 0.95 | PARP1 (0.47) | PARP1ALOX5GRIN2DGRIN3BGRIN1 | |
| SCHEMBL19994341 | 0.95 | PARP1 (0.47) | PARP1ALOX5GRIN2DGRIN3BGRIN1 | |
| SCHEMBL20687962 | 0.81 | PARP1 (0.49) | PARP1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL23967004 | 0.80 | PARP1 (0.48) | PARP1CNR2ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL20153301 | 0.80 | RECQL (0.60) | PARP1ALOX5CNR2ALDH1A1CYP1A2 | |
| SCHEMBL20889900 | 0.80 | PARP1 (0.45) | PARP1CNR2ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL536743 | 0.80 | PARP1 (0.57) | PARP1CNR2ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL19994396 | 0.78 | ALOX5 (0.40) | PARP1ALOX5GRIN2DGRIN3BGRIN1 | |
| SCHEMBL20502452 | 0.78 | ALOX5 (0.55) | PARP1ALOX5GRIN2DGRIN3BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228459-A1 | WEE1 INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228459-A1 | WEE1 INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228459-A1 | WEE1 INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2024-07-11 | — | — | US | disclosed |
| WO-2024131265-A1 | COMPOUND FOR TREATING PI3Kγ-MEDIATED DISEASES AND USE THEREOF | 中国科学院合肥物质科学研究院 | 2024-06-27 | — | — | WO | disclosed |
| CN-118239953-A | Compounds for the treatment of PI3K gamma mediated diseases and uses thereof | 中国科学院合肥物质科学研究院 | 2024-06-25 | — | — | CN | disclosed |
| US-11999765-B2 | Neuroactive steroids and their methods of use | SAGE THERAPEUTICS, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-11970514-B2 | Neuroactive steroids and their methods of use | SAGE THERAPEUTICS, INC. (US) | 2024-04-30 | — | — | US | disclosed |
| US-11912738-B2 | Neuroactive steroids and their methods of use | SAGE THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| CN-117186072-A | Compound for inhibiting phosphatidylinositol-3-kinase gamma subtype activity and preparation method and application thereof | 安驰达生物医药技术(广州)有限公司 | 2023-12-08 | — | — | CN | disclosed |
| US-20230322847-A1 | NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | SAGE THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20210246130-A1 | DUAL INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE DELTA & GAMMA | ASTRAZENECA AB (SE) | 2021-08-12 | — | — | US | disclosed |
| US-10961236-B2 | (S)-2-(1-cyclopropylethyl)-5-(4-methyl-2-((6-(2-oxopyrrolidin-1-yl)pyridin-2-yl)amino) thiazol-5-yl)-7-(methylsulfonyl)isoindolin-1-one as a phosphatidylinositol 3-kinase inhibitor | ASTRAZENECA AB (SE) | 2021-03-30 | — | — | US | disclosed |
| US-20200308164-A1 | 5-[2-(PYRIDIN-2-YLAMINO)-1,3-THIAZOL-5-YL]-2,3-DIHYDRO-1 H-ISOINDOL-1 -ONE DERIVATIVES AND THEIR USE AS DUAL INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE DELTA & GAMMA | ASTRAZENECA AB (SE) | 2020-10-01 | — | — | US | disclosed |
| EP-3694861-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Nuvation Bio Inc. (US) | 2020-08-19 | — | — | EP | disclosed |
| EP-3515910-B1 | 5-[2-(PYRIDIN-2-YLAMINO)-1,3-THIAZOL-5-YL]-2,3-DIHYDRO-1H-ISOINDOL-1-ONE DERIVATIVES AND THEIR USE AS DUAL INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE DELTA & GAMMA | ASTRAZENECA AB (SE) | 2020-07-15 | — | — | EP | disclosed |
| EP-3515910-A1 | 5-[2-(PYRIDIN-2-YLAMINO)-1,3-THIAZOL-5-YL]-2,3-DIHYDRO-1 H-ISOINDOL-1 -ONE DERIVATIVES AND THEIR USE AS DUAL INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE DELTA&GAMMA | Astrazeneca AB (SE) | 2019-07-31 | — | — | EP | disclosed |
| WO-2019074979-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | GIRAFPHARMA, LLC (US) | 2019-04-18 | — | — | WO | disclosed |
| WO-2019074979-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | GIRAFPHARMA, LLC (US) | 2019-04-18 | — | — | WO | disclosed |
| US-20190106427-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-04-11 | — | — | US | disclosed |
| WO-2018055040-A1 | 5-[2-(PYRIDIN-2-YLAMINO)-1,3-THIAZOL-5-YL]-2,3-DIHYDRO-1 H-ISOINDOL-1 -ONE DERIVATIVES AND THEIR USE AS DUAL INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE DELTA & GAMMA | ASTRAZENECA AB (SE) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308164-A1 | 5-[2-(PYRIDIN-2-YLAMINO)-1,3-THIAZOL-5-YL]-2,3-DIHYDRO-1 H-ISOINDOL-1 -ONE DERIVATIVES AND THEIR USE AS DUAL INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE DELTA & GAMMA | PIK3CD, PIK3CG, PDPK1 | PARP1 1325/4885ALOX5 2551/4885GRIN2D 1917/4885 |
| US-11970514-B2 | Neuroactive steroids and their methods of use | NR3C2, MC2R, NR3C1 | PARP1 4571/4885ALOX5 1047/4885GRIN2D 117/4885 |
| US-20230322847-A1 | NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | NR3C2, MC2R, NR3C1 | PARP1 4597/4885ALOX5 977/4885GRIN2D 107/4885 |
| US-11912738-B2 | Neuroactive steroids and their methods of use | NR3C2, MC2R, NR3C1 | PARP1 4571/4885ALOX5 1047/4885GRIN2D 117/4885 |
| US-10961236-B2 | (S)-2-(1-cyclopropylethyl)-5-(4-methyl-2-((6-(2-oxopyrrolidin-1-yl)pyridin-2-yl)amino) thiazol-5-yl)-7-(methylsulfonyl)isoindolin-1-one as a phosphatidylinositol 3-kinase inhibitor | PIK3CD, PIK3CB, PIK3CA | PARP1 1151/4885ALOX5 4091/4885GRIN2D 1205/4885 |
| US-11999765-B2 | Neuroactive steroids and their methods of use | NR3C2, MC2R, NR3C1 | PARP1 4620/4885ALOX5 961/4885GRIN2D 122/4885 |
| US-20240228459-A1 | WEE1 INHIBITORS AND USES THEREOF | WEE1, WEE2, DCLRE1B | PARP1 302/4885ALOX5 3173/4885GRIN2D 4729/4885 |
| US-20190106427-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, NME1 | PARP1 498/4885ALOX5 1684/4885GRIN2D 4799/4885 |
| US-20210246130-A1 | DUAL INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE DELTA & GAMMA | PIK3CD, PIK3CG, PRKCG | PARP1 1189/4885ALOX5 3158/4885GRIN2D 2015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.